FENC (Fennec Pharmaceuticals) Net earnings per share growth this year

FENC (Fennec) - company brandmark

Geopolitical instability regarding Asian supplies is creating volatility, which the GURU.Markets service reflects in the year-over-year change in EPS. The value of this indicator is 181.60. Risks associated with changes in chemotherapy protocols are mitigated by Pedmark's monopoly and FDA protection, ensuring Fennec Pharmaceuticals (FENC) achieves high returns within the narrow segment of hearing loss therapy.

Earnings per share growth in current year: Fennec Pharma (FENC) for 07/04/2022 - 11/12/2026

Financial and market metric breakdowns for Fennec Pharmaceuticals (FENC)

- stock quotes and analyst forecast:
Share Price Fennec Pharma|FENC - Analyst Consensus Forecast
- business market valuation indicators:
Market Valuation Fennec|FENC - Total Company Value
- company book value details:
Net Asset Value per Share Fennec Pharmaceuticals|FENC - Company Book Value|Market Value to Book Value Ratio fennecpharma.com|FENC - Aggregate Company Assets
- debt and liquidity details:
Debt to Capital Fennec Pharmaceuticals|FENC - Long-Term Debt to Capital|Short-Term Indebtedness to Equity fennecpharma.com|FENC - Company Total Debt|Debts to Book Value Fennec|FENC - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Fennec Pharmaceuticals|Intermediate Liquidity Ratio fennecpharma.com
- company profitability and valuation multiples indicators:
FENC - Net Profit|Expected Net Income Fennec Pharmaceuticals|FENC - P/E Multiple|Projected Price to Earnings Ratio Fennec|FENC - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Fennec|FENC - Operating profit EBITDA|Net earnings per share (EPS TTM) Fennec Pharmaceuticals|FENC - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months fennecpharma.com|FENC - Net earnings per share growth this year|Expected net earnings per share growth next year Fennec Pharmaceuticals
Summary company analysis:FENC Fennec Pharma
Signature product of Fennec Pharmaceuticals

Investors utilize earnings per share dynamics to evaluate business scaling efficiency and the pace of net income capitalization. This indicator measures the percentage deviation of current EPS from the previous year's value, which, during the commercial expansion of PEDMARK and a lull in R&D at Fennec Pharmaceuticals (FENC), allows analysts to filter out market noise and identify real profitability through the year-over-year EPS trend.

Key competitors

Earnings per share growth this year INCY|HCM (HUTCHMED Ltd) - Earnings growth in current year|Net earnings per share growth this year Nuvation Corp (NUVB)|Earnings per share growth in current year Day One (DAWN)|MNPR - Earnings per share growth rate in current year|Earnings per share growth in current year Inhibrx Biosciences, Inc. INBX|I-Mab Biopharma Co., Ltd. - Earnings per share growth in current year|HRTX - Earnings per share growth in current year|Earnings per share growth rate in current year Nuvectis Pharma, Inc|CHRS: Earnings growth in current year|Net earnings per share change in current year corbuspharma.com CRBP|Net earnings per share growth this year CRDF|Earnings per share growth rate in current year BeyondSpring, Inc. BYSI|Net earnings per share growth this year BCAB (BioAtla, Inc.)|LIXT (Lixte Biotechnology, Inc.) - Earnings per share increase in current year|Citius Pharmaceuticals, Inc. - Net earnings per share growth this year|Net earnings per one share growth for the current year CLRB (cellectar.com)|BioLineRx - Earnings growth in current year|Earnings per share increase in current year CANF (Can-Fite BioPharma Ltd)|APRE: Earnings growth in current year|Earnings per share growth rate in current year Kazia Therapeutics Limited (KZIA)|Earnings per share growth in current year Silexion Therapeutics Corp.|NCNA: Earnings per share increase in current year|Earnings growth in current year CMRX|Earnings growth in current year Cyclacel Pharmaceuticals, Inc. (CYCC)|Earnings per share growth in current year G1 Therapeutics GTHX|KRON (Kronos Bio Corporation) - Earnings per share trend in current year|KTRA: Net earnings per share growth this year|Earnings per share growth rate in current year oncternal.com|PRTG: Earnings growth in current year